Retatrutide
-
Best Peptides for Fat Loss Research: What the Studies Actually Show
Fat loss is the one corner of peptide research with genuine large-scale human trials — and also the one with the loudest marketing. This field spans everything from FDA-approved incretin drugs tested in thousands of patients to a fragment with a single discontinued human program and a mitochondrial peptide studied only in mice. In this…
-
Tirzepatide vs Retatrutide: What’s the Difference?
Tirzepatide and retatrutide are the two most closely compared molecules in incretin-based metabolic research — and the source of frequent confusion. Both are single-molecule peptides engineered to activate multiple gut-hormone receptors, both are studied for weight and glycemic outcomes, and both carry Eli Lilly’s development pedigree. But they differ in a way that matters enormously…
-
Retatrutide Peptide Research: Benefits, Studies, and Evidence
Retatrutide (formerly LY3437943) is a synthetic peptide researched as a triple agonist of the GIP, GLP-1, and glucagon receptors — the first single molecule to combine all three metabolic hormone pathways. Developed by Eli Lilly, it extends dual incretin agonism with glucagon-receptor activation, hypothesized to add energy expenditure and hepatic fat reduction to the incretin…